James Woodruff Lillie - 25 Oct 2025 Form 3 Insider Report for MapLight Therapeutics, Inc. (MPLT)

Role: Chief Scientific Officer
Signature: /s/ Kristopher L. Hanson, Attorney-in-Fact
Issuer symbol: MPLT
Transactions as of: 25 Oct 2025
Net transactions value: $0
Form type: 3
Filing time: 27 Oct 2025, 16:44:34 UTC
Next filing: 28 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lillie James Woodruff	Chief Scientific Officer	C/O MAPLIGHT THERAPEUTICS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY	/s/ Kristopher L. Hanson, Attorney-in-Fact	27 Oct 2025	0001728746

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MPLT	Voting Common Stock						303,648	25 Oct 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MPLT	Stock Option (Right to Buy)							25 Oct 2025	Voting Common Stock	22,082	$2.86	Direct	F3
holding	MPLT	Stock Option (Right to Buy)							25 Oct 2025	Voting Common Stock	17,857	$5.55	Direct	F3
holding	MPLT	Stock Option (Right to Buy)							25 Oct 2025	Voting Common Stock	13,988	$5.55	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 260,940 Restricted Stock Units (RSUs). Of the RSUs, (i) as to 51,196 RSUs, 30,931 vested in connection with the Issuer's IPO and the remainder will vest in quarterly installments through July 1, 2027; (ii) as to 22,935 RSUs, 12,423 vested in connection with the Issuer's IPO and the remainder will vest in quarterly installments through October 1, 2027; (iii) as to 98,362 RSUs, 43,033 vested in connection with the Issuer's IPO and the remainder will vest in quarterly installments through January 1, 2028; and (iv) as to 88,447 RSUs, 14/48ths will vest on July 1, 2026 and the remainder will vest in 12 quarterly installments thereafter. With respect to all RSUs, vesting is subject to the Reporting Person's continued service through each vesting date.
F2	Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
F3	This stock option vests over a period of four years, with 1/4th of the shares underlying the option vested on the one-year anniversary of February 16, 2022, the vesting commencement date, and 1/48th of the shares underlying the option vesting on a monthly basis thereafter, subject to the Reporting Person's continued service through each vesting date.
F4	This stock option vests over a period of four years, with 1/4th of the shares underlying the option vested on the one-year anniversary of March 11, 2022, the vesting commencement date, and 1/48th of the shares underlying the option vesting on a monthly basis thereafter, subject to the Reporting Person's continued service through each vesting date.